http://orcid.org/0000-0002-1068-4261
References
- Adcock DM, Gosselin R. (2015). Direct oral anticoagulants (DOACs) in the laboratory: 2015 review. Thromb Res 136:7–12.
- Chan KE, Giugliano RP, Patel MR, et al. (2016). Nonvitamin K anticoagulant agents in patients with advanced chronic kidney disease or on dialysis with AF. J Am Coll Cardiol 67:2888–99.
- Graff J, Harder S. (2013). Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment. Clin Pharmacokinet 52:243–54.
- Harder S. (2014). Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism. Thromb J 12:22.
- Hariharan S, Madabushi R. (2012). Clinical pharmacology basis of deriving dosing recommendations for dabigatran in patients with severe renal impairment. J Clin Pharmacol 52:119S–25S.
- Kubitza D, Becka M, Mueck W, et al. (2010). Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol 70:703–12.
- Lehr T, Haertter S, Liesenfeld KH, et al. (2012). Dabigatran etexilate in atrial fibrillation patients with severe renal impairment: dose identification using pharmacokinetic modeling and simulation. J Clin Pharmacol 52:1373–8.
- Liesenfeld KH, Lehr T, Dansirikul C, et al. (2011). Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost 9:2168–75.
- Miura T, Suemizu H, Goto M, et al. (2018). Human urinary concentrations of monoisononyl phthalate estimated using physiologically based pharmacokinetic modeling and experimental pharmacokinetics in humanized-liver mice orally administered with diisononyl phthalate. Xenobiotica in press. doi: 10.1080/00498254.2018.1471753.
- Miyagata Y, Nakai K, Sugiyama Y. (2011). Clinical significance of combined CYP2C9 and VKORC1 genotypes in Japanese patients requiring warfarin. Int Heart J 52:44–9.
- Murayama N, Suemizu H, Uehara S, et al. (2018). Association of pharmacokinetic profiles of lenalidomide in human plasma simulated using pharmacokinetic data in humanized-liver mice with liver toxicity detected by human serum albumin RNA. J Toxicol Sci 43:369–75.
- Nakamura M, Yamada N, Ito M. (2017). Direct oral anticoagulants for the treatment of venous thromboembolism in Japan. J Atheroscler Thromb 24:560–5.
- Parasrampuria DA, Truitt KE. (2016). Pharmacokinetics and pharmacodynamics of edoxaban, a non-vitamin K antagonist oral anticoagulant that inhibits clotting factor Xa . Clin Pharmacokinet 55:641–55.
- Raghavan N, Frost CE, Yu Z, et al. (2009). Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 37:74–81.
- Rose DK, Bar B. (2018). Direct oral anticoagulant agents: pharmacologic profile, indications, coagulation monitoring, and reversal agents. J Stroke Cerebrovasc Dis 27:2049–58.
- Shimizu M, Suemizu H, Mitsui M, et al. (2017). Metabolic profiles of pomalidomide in human plasma simulated with pharmacokinetic data in control and humanized-liver mice. Xenobiotica 47:844–8.
- Xu R, Ge W, Jiang Q. (2018). Application of physiologically based pharmacokinetic modeling to the prediction of drug-drug and drug-disease interactions for rivaroxaban. Eur J Clin Pharmacol 74:755–65.
- Yamahira N, Frost C, Fukase H, et al. (2014). Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of apixaban in healthy Japanese male subjects. Int J Clin Pharmacol Ther 52:564–73.
- Yamazaki-Nishioka M, Shimizu M, Suemizu H, et al. (2018). Human plasma metabolic profiles of benzydamine, a flavin-containing monooxygenase probe substrate, simulated with pharmacokinetic data from control and humanized-liver mice. Xenobiotica 48:117–23.
- Zhang WL, Lou D, Zhang DT, et al. (2016). Determination of rivaroxaban, apixaban and edoxaban in rat plasma by UPLC-MS/MS method. J Thromb Thrombolysis 42:205–11.